Open AccessS0768 Early and Durable Symptom Control in Patients With Moderately to Severely Active Ulcerative Colitis Treated With Etrasimod (APD334) in the Phase 2 OASIS Trial and Open Label Extension
Author(s) -
Michael Chiorean,
Séverine Vermeire,
Julián Panés,
Laurent PeyrinBiroulet,
Jinkun Zhang,
Bruce E. Sands,
C. H. Cabell,
Snehal Naik,
William J. Sandborn
Publication year - 2020
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000705120.52073.1b
Subject(s) - medicine , gastroenterology , ulcerative colitis , placebo , open label , clinical trial , clinical endpoint , surgery , disease , alternative medicine , pathology